C
CrystalGenomics
Structural chemoproteomics-based drug discovery and development company in seoul, korea
About CrystalGenomics
CG Invites is a pioneering biopharmaceutical company dedicated to the development of innovative drugs aimed at improving patients' quality of life. Operating in the global biopharma market, CG Invites leverages advanced structural proteomics technology to discover and develop novel lead compounds for diseases with high unmet needs. The company's core technologies include Structural ChemoProteomics (SCP) and Structural Protein Solutions (SPS), which enable the precise determination of disease-causing protein structures and the identification of potential drug candidates. CG Invites primarily serves patients and healthcare providers, focusing on therapeutic areas where existing treatments are inadequate. The business model revolves around research and development, with a significant portion of its revenue generated through licensing deals and partnerships with other pharmaceutical companies. With a workforce composed of 95% life science professionals holding advanced degrees, CG Invites is well-positioned to continue its growth and innovation in the biopharma sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2000
- Headquarters
- Seoul, South Korea
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 57.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2014 | $13M | $51M | Undisclosed | — |
| SERIES A✓Equity / VC | Jan 2012 | $2.6M | $10M | Korea Seoul Life Science Fund | — |
Growth signals
Latest recorded traffic for CrystalGenomics is 580 monthly website visits, down 67.8% over the last three months. CrystalGenomics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Korea Seoul Life Science Fund
Other known investors1 additional known investor
Synergy IB Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about CrystalGenomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CrystalGenomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.